id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-D-4447-0001,FDA,FDA-2019-D-4447,"Transdermal and Topical Delivery Systems—Product Development and
Quality Considerations; Draft Guidance for Industry; Availability",Notice,Notice of Availability,2019-11-21T05:00:00Z,2019,11,2019-11-21T05:00:00Z,2020-02-20T04:59:59Z,2020-02-21T02:02:24Z,2019-25246,0,0,090000648418f9ef
FDA-2019-D-4447-0002,FDA,FDA-2019-D-4447,Transdermal and Topical Delivery Systems - Product Development and Quality Considerations Guidance for Industry DRAFT GUIDANCE,Other,Guidance,2019-11-21T05:00:00Z,2019,11,2019-11-21T05:00:00Z,,2024-11-12T23:12:50Z,,1,0,090000648418fed8